Serveur d'exploration sur Heinrich Schütz

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D3 analogue shows relation to promoter selectivity

Identifieur interne : 000D21 ( Main/Exploration ); précédent : 000D20; suivant : 000D22

Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D3 analogue shows relation to promoter selectivity

Auteurs : Carina Danielsson [Suisse] ; Ida S. Mathiasen [Danemark] ; Sharon Y. James [Royaume-Uni] ; Sepideh Nayeri [Suisse] ; Claus Bretting [Danemark] ; Christina M Rk Hansen [Danemark] ; Kay W. Colston [Royaume-Uni] ; Carsten Carlberg [Suisse, Allemagne]

Source :

RBID : ISTEX:68A7D00AF2744072C4523DFF390C269BD5718A2C

English descriptors

Abstract

The biologically active form of vitamin D3, the nuclear hormone 1α,25‐dihydroxyvitamin D3 (VD), is an important regulator of cellular growth, differentiation, and death. The hormone mediates its action through the activation of the transcription factor VDR, which is a member of the superfamily of nuclear receptors. In most cases the ligand‐activated VDR is found in complex with the retinoid X receptor (RXR) and stimulates gene transcription mainly from VD response elements (VDREs) that are formed by two hexameric core binding motifs and are arranged either as a direct repeat spaced by three nucleotides (DR3) or as an inverted palindrome spaced by nine nucleotides (IP9). The two VD analogues CB1093 and EB1089 are both very potent inhibitors of the proliferation of MCF‐7 cultured breast cancer cells displaying approximately 100‐fold lower IC50 values (0.1 nM) than the natural hormone. In addition, CB1093 is even more potent in vivo than EB1089 in producing regression of experimental mammary tumors. Moreover, both VD analogues induce apoptosis in MCF‐7 cells, but CB1093 is effective at concentrations approximately 10‐fold lower than EB1089. In accordance, the reduction of Bcl‐2 protein expression showed CB1093 to be more potent than EB1089. This suggests that the antiproliferative effect of CB1093 may be related mainly to its apoptosis inducing effect, whereas EB1089 may preferentially have effects on growth arrest. EB1089 is known to result in a selectivity for the activation of IP9‐type VDREs, whereas CB1093 shows a preference for the activation of DR3‐type VDREs. This promoter selectivity suggests that the effects of VD and its analogues on growth arrest and the induction of apoptosis may be mediated by different primary VD responding genes. In conclusion, CB1093 was found to be a potent inhibitor of rat mammary tumor growth in vivo. CB1093 also displayed a high potency in vitro in the induction of apoptosis, a process that may be linked to a promoter selectivity for DR3‐type VDREs. J. Cell. Biochem. 66: 552–562, 1997. © 1997 Wiley‐Liss, Inc.

Url:
DOI: 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D3 analogue shows relation to promoter selectivity</title>
<author>
<name sortKey="Danielsson, Carina" sort="Danielsson, Carina" uniqKey="Danielsson C" first="Carina" last="Danielsson">Carina Danielsson</name>
</author>
<author>
<name sortKey="Mathiasen, Ida S" sort="Mathiasen, Ida S" uniqKey="Mathiasen I" first="Ida S." last="Mathiasen">Ida S. Mathiasen</name>
</author>
<author>
<name sortKey="James, Sharon Y" sort="James, Sharon Y" uniqKey="James S" first="Sharon Y." last="James">Sharon Y. James</name>
</author>
<author>
<name sortKey="Nayeri, Sepideh" sort="Nayeri, Sepideh" uniqKey="Nayeri S" first="Sepideh" last="Nayeri">Sepideh Nayeri</name>
</author>
<author>
<name sortKey="Bretting, Claus" sort="Bretting, Claus" uniqKey="Bretting C" first="Claus" last="Bretting">Claus Bretting</name>
</author>
<author>
<name sortKey="Hansen, Christina M Rk" sort="Hansen, Christina M Rk" uniqKey="Hansen C" first="Christina M Rk" last="Hansen">Christina M Rk Hansen</name>
</author>
<author>
<name sortKey="Colston, Kay W" sort="Colston, Kay W" uniqKey="Colston K" first="Kay W." last="Colston">Kay W. Colston</name>
</author>
<author>
<name sortKey="Carlberg, Carsten" sort="Carlberg, Carsten" uniqKey="Carlberg C" first="Carsten" last="Carlberg">Carsten Carlberg</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:68A7D00AF2744072C4523DFF390C269BD5718A2C</idno>
<date when="1997" year="1997">1997</date>
<idno type="doi">10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D</idno>
<idno type="url">https://api.istex.fr/document/68A7D00AF2744072C4523DFF390C269BD5718A2C/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000C72</idno>
<idno type="wicri:Area/Main/Curation">000C54</idno>
<idno type="wicri:Area/Main/Exploration">000D21</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Exploration">000D21</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D3 analogue shows relation to promoter selectivity</title>
<author>
<name sortKey="Danielsson, Carina" sort="Danielsson, Carina" uniqKey="Danielsson C" first="Carina" last="Danielsson">Carina Danielsson</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève</wicri:regionArea>
<wicri:noRegion>Genève</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mathiasen, Ida S" sort="Mathiasen, Ida S" uniqKey="Mathiasen I" first="Ida S." last="Mathiasen">Ida S. Mathiasen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Departments of Chemistry and Biochemistry, LEO Pharmaceutical Products, Ballerup</wicri:regionArea>
<wicri:noRegion>Ballerup</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="James, Sharon Y" sort="James, Sharon Y" uniqKey="James S" first="Sharon Y." last="James">Sharon Y. James</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Biochemistry, St. George's Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Nayeri, Sepideh" sort="Nayeri, Sepideh" uniqKey="Nayeri S" first="Sepideh" last="Nayeri">Sepideh Nayeri</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève</wicri:regionArea>
<wicri:noRegion>Genève</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bretting, Claus" sort="Bretting, Claus" uniqKey="Bretting C" first="Claus" last="Bretting">Claus Bretting</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Departments of Chemistry and Biochemistry, LEO Pharmaceutical Products, Ballerup</wicri:regionArea>
<wicri:noRegion>Ballerup</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Hansen, Christina M Rk" sort="Hansen, Christina M Rk" uniqKey="Hansen C" first="Christina M Rk" last="Hansen">Christina M Rk Hansen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Departments of Chemistry and Biochemistry, LEO Pharmaceutical Products, Ballerup</wicri:regionArea>
<wicri:noRegion>Ballerup</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Colston, Kay W" sort="Colston, Kay W" uniqKey="Colston K" first="Kay W." last="Colston">Kay W. Colston</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Clinical Biochemistry, St. George's Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Carlberg, Carsten" sort="Carlberg, Carsten" uniqKey="Carlberg C" first="Carsten" last="Carlberg">Carsten Carlberg</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève</wicri:regionArea>
<wicri:noRegion>Genève</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3">
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Current Address: Institut für Physiologische Chemie I, Heinrich‐Heine‐Universität Düsseldorf, Postfach 10 10 07, D‐40001 Düsseldorf</wicri:regionArea>
<placeName>
<region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region>
<region type="district" nuts="2">District de Düsseldorf</region>
<settlement type="city">Düsseldorf</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Journal of Cellular Biochemistry</title>
<title level="j" type="abbrev">J. Cell. Biochem.</title>
<idno type="ISSN">0730-2312</idno>
<idno type="eISSN">1097-4644</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1997-09-15">1997-09-15</date>
<biblScope unit="volume">66</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="552">552</biblScope>
<biblScope unit="page" to="562">562</biblScope>
</imprint>
<idno type="ISSN">0730-2312</idno>
</series>
<idno type="istex">68A7D00AF2744072C4523DFF390C269BD5718A2C</idno>
<idno type="DOI">10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D</idno>
<idno type="ArticleID">JCB14</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0730-2312</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>apoptosis</term>
<term>breast cancer</term>
<term>control of proliferation</term>
<term>promoter selectivity</term>
<term>regulation of transcription</term>
<term>tumor regression</term>
<term>vitamin D3 analogues</term>
<term>vitamin D3 receptor</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The biologically active form of vitamin D3, the nuclear hormone 1α,25‐dihydroxyvitamin D3 (VD), is an important regulator of cellular growth, differentiation, and death. The hormone mediates its action through the activation of the transcription factor VDR, which is a member of the superfamily of nuclear receptors. In most cases the ligand‐activated VDR is found in complex with the retinoid X receptor (RXR) and stimulates gene transcription mainly from VD response elements (VDREs) that are formed by two hexameric core binding motifs and are arranged either as a direct repeat spaced by three nucleotides (DR3) or as an inverted palindrome spaced by nine nucleotides (IP9). The two VD analogues CB1093 and EB1089 are both very potent inhibitors of the proliferation of MCF‐7 cultured breast cancer cells displaying approximately 100‐fold lower IC50 values (0.1 nM) than the natural hormone. In addition, CB1093 is even more potent in vivo than EB1089 in producing regression of experimental mammary tumors. Moreover, both VD analogues induce apoptosis in MCF‐7 cells, but CB1093 is effective at concentrations approximately 10‐fold lower than EB1089. In accordance, the reduction of Bcl‐2 protein expression showed CB1093 to be more potent than EB1089. This suggests that the antiproliferative effect of CB1093 may be related mainly to its apoptosis inducing effect, whereas EB1089 may preferentially have effects on growth arrest. EB1089 is known to result in a selectivity for the activation of IP9‐type VDREs, whereas CB1093 shows a preference for the activation of DR3‐type VDREs. This promoter selectivity suggests that the effects of VD and its analogues on growth arrest and the induction of apoptosis may be mediated by different primary VD responding genes. In conclusion, CB1093 was found to be a potent inhibitor of rat mammary tumor growth in vivo. CB1093 also displayed a high potency in vitro in the induction of apoptosis, a process that may be linked to a promoter selectivity for DR3‐type VDREs. J. Cell. Biochem. 66: 552–562, 1997. © 1997 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Danemark</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region>
<li>Angleterre</li>
<li>District de Düsseldorf</li>
<li>Grand Londres</li>
<li>Rhénanie-du-Nord-Westphalie</li>
</region>
<settlement>
<li>Düsseldorf</li>
<li>Londres</li>
</settlement>
</list>
<tree>
<country name="Suisse">
<noRegion>
<name sortKey="Danielsson, Carina" sort="Danielsson, Carina" uniqKey="Danielsson C" first="Carina" last="Danielsson">Carina Danielsson</name>
</noRegion>
<name sortKey="Carlberg, Carsten" sort="Carlberg, Carsten" uniqKey="Carlberg C" first="Carsten" last="Carlberg">Carsten Carlberg</name>
<name sortKey="Nayeri, Sepideh" sort="Nayeri, Sepideh" uniqKey="Nayeri S" first="Sepideh" last="Nayeri">Sepideh Nayeri</name>
</country>
<country name="Danemark">
<noRegion>
<name sortKey="Mathiasen, Ida S" sort="Mathiasen, Ida S" uniqKey="Mathiasen I" first="Ida S." last="Mathiasen">Ida S. Mathiasen</name>
</noRegion>
<name sortKey="Bretting, Claus" sort="Bretting, Claus" uniqKey="Bretting C" first="Claus" last="Bretting">Claus Bretting</name>
<name sortKey="Hansen, Christina M Rk" sort="Hansen, Christina M Rk" uniqKey="Hansen C" first="Christina M Rk" last="Hansen">Christina M Rk Hansen</name>
</country>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="James, Sharon Y" sort="James, Sharon Y" uniqKey="James S" first="Sharon Y." last="James">Sharon Y. James</name>
</region>
<name sortKey="Colston, Kay W" sort="Colston, Kay W" uniqKey="Colston K" first="Kay W." last="Colston">Kay W. Colston</name>
</country>
<country name="Allemagne">
<region name="Rhénanie-du-Nord-Westphalie">
<name sortKey="Carlberg, Carsten" sort="Carlberg, Carsten" uniqKey="Carlberg C" first="Carsten" last="Carlberg">Carsten Carlberg</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D21 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D21 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    SchutzV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:68A7D00AF2744072C4523DFF390C269BD5718A2C
   |texte=   Sensitive induction of apoptosis in breast cancer cells by a novel 1,25‐dihydroxyvitamin D3 analogue shows relation to promoter selectivity
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Mon Feb 8 17:34:10 2021. Site generation: Mon Feb 8 17:41:23 2021